New targeted chemotherapeutics are urgently needed to minimize off-target toxicity and
reduce the high-mortality rate associated with metastatic prostate cancer. Herein, we report …

Most patients with advanced prostate cancer (PCa) will develop metastatic castration-
resistant prostate cancer (mCRPC) after androgen deprivation therapy, at this time the tumor …

This work describes the enhancement of a novel antitumor therapeutic platform that
combines advantages from small-molecule drug conjugates (SMDCs) and antibody drug …

Herein, we report the modular synthesis and evaluation of a prostate-specific membrane
antigen (PSMA) targeted small molecule drug conjugate (SMDC) carrying the …

Prostate-specific membrane antigen (PSMA) continues to be an active biomarker for small-
molecule PSMA-targeted imaging and therapeutic agents for prostate cancer and various …

Background Several radiolabeled prostate-specific membrane antigen (PSMA) inhibitors
based on the lysine-urea-glutamate (KuE) motif as the pharmacophore proved to be suitable …

Small-molecule drug conjugates (SMDCs) are compounds in which a therapeutic payload is
conjugated to a targeting vector, for specific delivery to the tumor site. This promising …

Prostate-specific membrane antigen (PSMA) is a tumor-associated protein that has been
successfully targeted with small organic ligands and monoclonal antibodies. Pluvicto™ is a …

In the past two decades, extensive efforts have been made to develop agents targeting
prostate-specific membrane antigen (PSMA) for prostate cancer imaging and therapy. To …

To investigate the effect of carbohydrate moieties on the pharmacokinetic profile of prostate-
specific membrane antigen (PSMA) inhibitors, carbohydrated derivatives of the established …